In 2023, Director Kathi Vidal exercised her authority to conduct sua sponte director reviews of Patent Trial and Appeal Board (PTAB) decisions and addressed a wide range of issues that will impact PTAB practitioners. Many of these sua sponte director reviews related to inter partes review (IPR) institution decisions, which are generally not reviewed at the PTAB and, in nearly all circumstances, are not appealable. These sua sponte director reviews provide important guidance to practitioners on many issues of PTAB practice, including the application of Fintiv, the use of applicant-admitted prior art, and the Advanced Bionics standard.

Director review is a proceeding in which the director of the U.S. Patent and Trademark Office (USPTO) reviews an aspect of a PTAB decision before any appeal to the Federal Circuit. The U.S. Supreme Court held that the Director must have the discretion to review all administrative patent judge decisions in United States v. Arthrex, 141 S. Ct. 1970 (2021), and the USPTO’s director review process is the practical implementation of that holding. The director may review any PTAB decision at the request of a party or sua sponte.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]